BD Gets FDA 510(k) Approval for EnCor EnCompass Breast Biopsy System

Key Takeaways BD received FDA 510(k) clearance for its EnCor EnCompass Breast Biopsy and Tissue Removal System.BDX plans an early 2026 launch, offering a multi-modality platform to improve flexibility and workflow.The system supports early detection with precision features designed to enhance confidence.Becton, Dickinson and Company(BDX) , popularly known as BD, recently announced that the FDA has granted 510(k) clearance for its EnCor EnCompass Breast Biopsy and Tissue Removal System. Anticipated to launch ...